Mercaptamine - NovaBiotics

Drug Profile

Mercaptamine - NovaBiotics

Alternative Names: Cysteamine - NovaBiotics; Lynovex; NM 001 - NovaBiotics; NM-001; NM-002; Nylexa

Latest Information Update: 03 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NovaBiotics
  • Class Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 22 Apr 2017 Antimicrobial data from the trials in Cystic fibrosis-associated respiratory tract infections (Adjunctive treatment) presented at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 27 Dec 2016 Preclinical development is ongoing, and phase I and phase IIb development of mercaptamine inhalation formulation is planned for Cystic fibrosis (NovaBiotics Pipeline, December 2016)
  • 01 Dec 2016 Phase-II clinical trials in Cystic fibrosis-associated respiratory tract infections (Adjunctive treatment) in United Kingdom (PO) (NCT03000348)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top